Source:http://linkedlifedata.com/resource/pubmed/id/20428925
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-11-18
|
| pubmed:abstractText |
Prediction of recurrence remains a challenge in histopathological benign/grade I tumors. Osteopontin (OPN) plays important roles in tumorigenesis, invasion, and metastasis of several human cancers. In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas. Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II). Cytoplasmic OPN staining was evaluated by means of immunohistochemistry (IHC) score and by use of the Allred-8-unit system. We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN. Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001). An OPN Allred score between 0 and 3 was associated with a recurrence-free time of more than 25 months. In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time. We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas. Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1573-7373
|
| pubmed:author |
pubmed-author:ChangChenC,
pubmed-author:ChenJia-HongJH,
pubmed-author:ChenKuan-YuKY,
pubmed-author:ChungMin-HueyMH,
pubmed-author:HuengDueng-YuanDY,
pubmed-author:JuDa-TongDT,
pubmed-author:LeeHorng-MoHM,
pubmed-author:LinChih-KungCK,
pubmed-author:LinGu-JiunGJ,
pubmed-author:LiuMing-YingMY,
pubmed-author:MaHsin-IHI,
pubmed-author:SytwuHuey-KangHK,
pubmed-author:TsengKuan-YinKY,
pubmed-author:YehYi-ShianYS,
pubmed-author:YenChe-HungCH
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
100
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
217-23
|
| pubmed:meshHeading |
pubmed-meshheading:20428925-Adult,
pubmed-meshheading:20428925-Aged,
pubmed-meshheading:20428925-Aged, 80 and over,
pubmed-meshheading:20428925-Disease-Free Survival,
pubmed-meshheading:20428925-Female,
pubmed-meshheading:20428925-Humans,
pubmed-meshheading:20428925-Immunohistochemistry,
pubmed-meshheading:20428925-Kaplan-Meier Estimate,
pubmed-meshheading:20428925-Male,
pubmed-meshheading:20428925-Meningeal Neoplasms,
pubmed-meshheading:20428925-Meningioma,
pubmed-meshheading:20428925-Middle Aged,
pubmed-meshheading:20428925-Neoplasm Recurrence, Local,
pubmed-meshheading:20428925-Osteopontin,
pubmed-meshheading:20428925-Tissue Array Analysis,
pubmed-meshheading:20428925-Tumor Markers, Biological,
pubmed-meshheading:20428925-World Health Organization,
pubmed-meshheading:20428925-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
|
| pubmed:affiliation |
Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center 325, Sec. 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan, ROC.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|